On June 24, the 16th Annual Meeting of the New Champions 2025 of the World Economic Forum (also known as the Summer Davos Forum) opened in Tianjin. The Chief Executive Officer of Sino Biopharmaceutical Limited ("Sino Biopharm") (1177.HK) was invited to attend the opening press conference and deliver a keynote speech. During the meeting, over 1,700 leaders from politics, business, and academia from around the world discussed innovative business solutions to global challenges under the theme of "Entrepreneurship in the New Era".

At the press conference, Mr. Eric Tse expressed his hope to break through cognitive limitations through full dialogue and exchange, bringing fresh nourishment and inspiration to the development of the industry and enterprises. He looks forward to promoting the "Entrepreneurship in the New Era" spirit, integrating resources with an open and cooperative mindset, and driving innovation in the industry ecosystem. He stated his hope that representatives from government agencies, enterprises, and academia, as well as all attendees, could interact and exchange ideas through the Davos platform to contribute more advanced wisdom to global economic growth.

In the "Turbocharging Clinical Trials" session, Mr. Eric Tse delivered a keynote speech on "Embracing AI Opportunities, Breaking Down Integration Barriers, and Fast-Tracking Innovative Drug R&D in the Asia-Pacific". He pointed out that leveraging the technological innovations brought by AI and promoting broader multilateral collaboration aimed at breaking down data barriers will be of extraordinary significance for China and the entire Asia-Pacific region.

Mr. Eric Tse stated that AI has initiated a new revolution in biomedicine. As a leading pharmaceutical company in China, Sino Biopharm has been continuously promoting digital transformation in recent years and has been a pioneer in fully embracing AI technology. In the drug discovery phase, AI models have shifted drug discovery from "finding a needle in a haystack" to "precision guidance", shortening R&D cycles and reducing costs. In the clinical development phase, AI has been integrated into all clinical application scenarios, leading to a comprehensive improvement in R&D efficiency. We are also exploring the use of AI agents to guide patients in the rational use of medication, achieving full-cycle health management for patients.

Mr. Eric Tse pointed out that the DEEP SEEK era of biopharmaceuticals is approaching, but the current issue of data silos across organizations, especially across countries, remains a key "choke point" limiting the deeper adoption of AI. He proposed the establishment of an "Asia-Pacific Clinical Recognition Alliance (APCRA)" with unified standards and data sharing across the entire Asia-Pacific region, actively encouraging participation from pharmaceutical companies and medical institutions in Japan, Singapore, Thailand, and other regions along the "Belt and Road". The alliance will establish a credible cross-border clinical data recognition mechanism, which will not only accelerate international clinical approvals and the translation of innovative achievements but also unlock multiple values by speeding up collaborative implementation, innovating regulatory models, enhancing regional competitiveness, and strengthening industrial resilience.

On the afternoon of June 25, Mr. Eric Tse will also deliver a keynote speech in the "Who Will Lead the Bioeconomy" session. Please stay tuned.

Declaration:

The copyright of this article is owned by the original author or our company. Unauthorized use by means of reprinting, copying, filming, adapting, or compiling is prohibited. The portrait rights of the individuals appearing in this article belong to the individuals themselves. Unauthorized use is prohibited.

Source: 2025 Summer Davos Forum